Emerging Markets Earnings Roundup: Sanofi, Teva (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.
You may also be interested in...
Sanofi Fires Up Late-Stage R&D After Growth Rekindled in Fourth Quarter
Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.
As Sun Sets On Copaxone, Teva Looks To New BD Horizons
Acting CEO Eyal Desheh said the company will be more open-minded about business development during the company’s fourth quarter financial call Feb. 6. Investors will have to wait to hear from incoming CEO Erez Vigodman for any new strategy to be articulated, however.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.